LYEL vs. OLMA, CALT, KRRO, ATXS, SLN, MLYS, SIGA, ZYME, ALXO, and YMAB
Should you be buying Lyell Immunopharma stock or one of its competitors? The main competitors of Lyell Immunopharma include Olema Pharmaceuticals (OLMA), Calliditas Therapeutics AB (publ) (CALT), Korro Bio (KRRO), Astria Therapeutics (ATXS), Silence Therapeutics (SLN), Mineralys Therapeutics (MLYS), SIGA Technologies (SIGA), Zymeworks (ZYME), ALX Oncology (ALXO), and Y-mAbs Therapeutics (YMAB). These companies are all part of the "pharmaceutical preparations" industry.
Lyell Immunopharma (NASDAQ:LYEL) and Olema Pharmaceuticals (NASDAQ:OLMA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, community ranking, analyst recommendations, valuation, profitability, risk, institutional ownership and media sentiment.
Lyell Immunopharma presently has a consensus target price of $5.50, suggesting a potential upside of 136.05%. Olema Pharmaceuticals has a consensus target price of $21.43, suggesting a potential upside of 116.45%. Given Lyell Immunopharma's higher probable upside, research analysts clearly believe Lyell Immunopharma is more favorable than Olema Pharmaceuticals.
Olema Pharmaceuticals received 10 more outperform votes than Lyell Immunopharma when rated by MarketBeat users. Likewise, 59.46% of users gave Olema Pharmaceuticals an outperform vote while only 54.55% of users gave Lyell Immunopharma an outperform vote.
Lyell Immunopharma has a beta of -0.56, suggesting that its stock price is 156% less volatile than the S&P 500. Comparatively, Olema Pharmaceuticals has a beta of 2.1, suggesting that its stock price is 110% more volatile than the S&P 500.
In the previous week, Lyell Immunopharma had 2 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 5 mentions for Lyell Immunopharma and 3 mentions for Olema Pharmaceuticals. Olema Pharmaceuticals' average media sentiment score of 0.69 beat Lyell Immunopharma's score of 0.54 indicating that Olema Pharmaceuticals is being referred to more favorably in the news media.
Olema Pharmaceuticals has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -180,486.14%. Lyell Immunopharma's return on equity of -32.67% beat Olema Pharmaceuticals' return on equity.
Olema Pharmaceuticals has lower revenue, but higher earnings than Lyell Immunopharma. Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.
66.1% of Lyell Immunopharma shares are held by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are held by institutional investors. 24.0% of Lyell Immunopharma shares are held by company insiders. Comparatively, 23.5% of Olema Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Olema Pharmaceuticals beats Lyell Immunopharma on 9 of the 17 factors compared between the two stocks.
Get Lyell Immunopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for LYEL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LYEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lyell Immunopharma Competitors List
Related Companies and Tools
